Table 1.
Characteristics of the included studies.
| Author | Study | Year | Type of Study | Stage of Disease | Endpoints Available for Inclusion | Treatment | Chemotherapy Regimen |
|---|---|---|---|---|---|---|---|
| Fasching et al. [22] | GeparPLA | 2020 | Subgroup of phase 2 RCT | I-III | pCR; toxicity | PCb→EC | P 80 mg/m2 weekly + Cb AUC2 weekly for 12 weeks, followed by EC. |
| Mayer et al. [23] | TBCRC030 | 2020 | Subgroup of phase 2 RCT | I-III | pCR; RCB | Cisplatin | Cisplatin 75 mg/m2 every 3 weeks |
| Yuan et al. [24] | NCT01525966 | 2020 | Phase 2 | II-III | pCR; RCB; 3-year OS; 3-year DFS | Cb + nab-P | P 80 mg/m2 weekly for 12 doses + Cb AUC 6 every 3 weeks for four cycles |
| Sharma et al. [25] | NeoSTOP | 2020 | Phase 2 RCT | I-III | pCR; RCB; OS; toxicity; event-free | Arm A: PCb→AC; Arm B: DCb | Arm A: P 80 mg/m2 weekly for 12 weeks + Cb AUC6 every 3 weeks for four cycles followed by doxorubicin 60 mg/m2 + cyclophosphamide 600 mg/m2 every 14 days for four cycles Arm B: D 75 mg/m2 + Cb AUC6 every 3 weeks for six cycles |
| Fontaine et al. [26] | BSMO | 2019 | phase 2 | II-III | pCR; toxicity | PCb→EC | P 80 mg/m2 weekly concurrent with weekly Cb AUC = 2 for 12 weeks, followed by bi-weekly epirubicin (90 mg/m2) and cyclophosphamide (600 mg/m2) |
| Hahnen et al. [28], Loibl.S et al. [27] | Gepar Sixto | 2017, 2018 |
Phase 2 RCT | II-III | pCR, DFS | PCb + doxorubicin + bevacizumab | Cb AUC5 + P 80 mg/m2 + doxorubicin 20 mg/m2 weekly for 18 weeks + bevacizumab 15 mg/kg iv every 3 weeks |
| Loibl et al. [29], Telli et al. [30] | BrighTNess | 2018 | phase 3 RCT | II-III | pCR, toxicity | Segment I: PCb + veraparib Segment II: PCb |
Segment I: P 80 mg/m2 weekly for 12 doses + Cb AUC 6 every 3 weeks for four cycles + veraparib 50 mg orally twice a day. Segment II: P 80 mg/m2 weekly for 12 doses + Cb AUC 6 every 3 weeks for four cycles |
| Sella et al. [35] | 2018 | Clinical trial | I-III | pCR | ddAC→PCb | Four cycles of doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) every 2 weeks followed by 12 weekly cycles of P (80/m2) with Cb (AUC 1.5) | |
| Sharma et al. [31] | PROGECT | 2017 | Clinical trial | I-III | pCR, RCB | DCb | Six cycles of Cb AUC 6 + D 75 mg/m2 every 21 days |
| Connolly et al. [32] | TBCRC 008 | 2016 | Phase 2 RCT | I-III | pCR | Cb + nab-P ± vorinostat | Not available |
| Telli et al. [33] | PrECOG 0105 | 2015 | Phase 2 | I-IIIA | pCR, RCB | Cb + gemcitabine + iniparib | Four cycles of Cb (on days 1 and 8) + gemcitabin (1000 mg/m2 on days 1 and 8), + iniparib (5.6 mg/Kg on days 1, 4, 8, and 11) every 21 days |
| Kaklamani et al. [34] | NCT01372579 | 2015 | Phase 2 | I-III | pCR, RCB | Cb + eribulin | Four cycles of Cb AUC 6 + eribulin 1.4 mg/m2 (day 1 and 8) every 21 days |
| Silver et al. [36] | 2010 | Clinical trial | II-III | pCR | Cisplatin | Four cycles of Cisplatin at 75 mg/m2 every 21 days |
Abbreviations: RCT: randomized controlled trial; pCR: pathological complete response; P: paclitaxel; Cb: carboplatin; EC: epirubicin/cyclophosphamide; RUC: area under the curve; RCB: residual cancer burden; OS: overall survival; DFS: disease-free survival; nab-P: nab-paclitaxel; AC: doxorubicin/cyclophosphamide; D: docetaxel; DCb: docetaxel/carboplatin; dd: dose dense.